2022
Substance use screening in transplant populations: Recommendations from a consensus workgroup
Jowsey-Gregoire S, Jannetto PJ, Jesse MT, Fleming J, Winder GS, Balliet W, Kuntz K, Vasquez A, Weinland S, Hussain F, Weinrieb R, Fireman M, Nickels MW, Peipert JD, Thomas C, Zimbrean PC. Substance use screening in transplant populations: Recommendations from a consensus workgroup. Transplantation Reviews 2022, 36: 100694. PMID: 35537285, DOI: 10.1016/j.trre.2022.100694.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersTransplant patientsDrug testingConsultation-liaison psychiatryTransplant populationTransplant teamClinical historyOptimal carePatient practicesPatientsCurrent laboratory testingAmerican SocietyDisordersTransplantationPharmacy communityPossible risksInsurance issuesLaboratory testingOngoing testingRiskCertain substancesGroup discussionsTestingSubstances
2018
Ovarian Stimulation and the Long-Term Risk of Cancer
Taylan E, Oktay K. Ovarian Stimulation and the Long-Term Risk of Cancer. 2018, 344-348. DOI: 10.1016/b978-0-12-801238-3.64898-5.Peer-Reviewed Original Research
2001
Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer
Partridge A, Burstein H, Winer E. Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer. JNCI Monographs 2001, 2001: 135-142. PMID: 11773307, DOI: 10.1093/oxfordjournals.jncimonographs.a003451.Peer-Reviewed Original ResearchConceptsLong-term side effectsSide effectsChemohormonal therapyAdjuvant chemotherapyShort-term side effectsEarly-stage breast cancerSide effect profileDuration of treatmentLong-term toxicityAdjuvant regimenLate complicationsEffect profileTherapy regimensBreast cancerChemotherapySpecific agentsTherapyToxic effectsPossible risksTreatmentPotential benefitsConsiderable variabilityRegimenRegimensComplications
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply